Business Wire

MN-KINDEVA-DRUG-DELIVERY

18.1.2024 15:01:35 CET | Business Wire | Press release

Share
Kindeva Drug Delivery Acquires Summit Biosciences, a Specialized Nasal Drug Development and Manufacturing Organization

Kindeva Drug Delivery (“Kindeva”), a global leader in drug-device combination products, announced today that it has acquired Summit Biosciences Inc. (“Summit”), an intranasal drug-delivery contract development and manufacturing organization (CDMO), from its founding family shareholders. Established in 2009, Summit has an extensive track record of innovation in the unit dose nasal spray market. The acquisition of Summit enhances Kindeva’s existing drug-delivery capabilities by adding a new drug-delivery platform, further expanding Kindeva’s ability to serve biopharma customers across a wider range of complex drug-device combination products (pulmonary, injectable, transdermal, and nasal).

“Nasal drug delivery is becoming a preferred dosage format for a growing number of indications, as it allows users to non-invasively administer medications in an acute or emergency setting,” said Kindeva CEO Milton Boyer. “Summit brings a differentiated understanding of how to effectively formulate drugs for nasal delivery and the capability to manufacture them at commercial scale. This addition not only fits Kindeva’s ambition to be a global leader in the drug-device combination products CDMO market, but also expands the toolbox we can offer our customers to help improve patient outcomes and experience of care globally.”

Departing Summit Chairman and CEO Richard D. Cohen added, “Joining Kindeva strengthens our ability to deliver best-in-class nasal product development and manufacturing. Under Kindeva’s leadership, our dedicated and talented workforce will further drive our founder’s vision of increasing the availability of nasal drug-delivery options.”

Summit’s 55,000-square-foot cGMP facility in Lexington (Kentucky) adds to Kindeva’s global manufacturing footprint of nine development and manufacturing facilities across the U.S. and U.K. The facility is approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) and features specialized laboratories and integrated manufacturing operations with a long track record in bringing intranasal medicines to market.

Kirkland & Ellis acted as legal counsel to Kindeva. Frost Brown Todd acted as legal counsel, and Bourne Partners served as the exclusive financial advisor, to Summit.

About Kindeva Drug Delivery

Kindeva is a global contract development manufacturing organization (CDMO) focused on drug-device combination products. The company develops and manufactures products across a broad range of drug-delivery formats, including pulmonary & nasal, injectable, and transdermal. Kindeva’s service offerings span early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. Kindeva serves a global client base from our nine manufacturing, research, and development facilities located in the U.S. and U.K. For more information, please visit www.kindevadd.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240117554516/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Cessna Citation CJ3 Gen3 Achieves First Flight, Advancing Next-Generation Light Jet Toward Certification29.7.2026 18:31:00 CEST | Press release

All three Citation Gen3 light jets are now in flight testing, bringing Garmin Emergency Autoland and customer-inspired enhancements to the next generation of business aviation. Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, recently achieved a key milestone as the Cessna Citation CJ3 Gen3 prototype aircraft completed its first flight, advancing the next-generation light jet toward certification. With this milestone, all three next-generation Citation light jets — the CJ4 Gen3, CJ3 Gen3 and M2 Gen3 — have entered flight testing, demonstrating continued momentum across the Cessna next-generation light jet portfolio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729333762/en/ Cessna Citation CJ3 Gen3 achieves first flight, advancing next-generation light jet toward certification. (Photo credit: Textron Aviation) “This achievement continues the forward momentum of the CJ3 Gen3 program and reflects the discipline,

SES Launches Multi-Orbit Satellite Connectivity on LATAM Airbus, Embraer Fleet29.7.2026 17:30:00 CEST | Press release

SES, a leading space solutions company, was selected by LATAM Airlines to provide multi-orbit inflight connectivity service to its growing fleet of Airbus and Embraer aircraft, solidifying SES’s position as the top provider of multi-orbit broadband service in the Americas and around the world. “LATAM’s passengers will soon benefit from reliable, multi-orbit satellite connectivity that will provide the same fast and dependable internet access they enjoy at home no matter where or when they fly. SES’s partnerships with airlines like LATAM highlight how carriers throughout the Americas are leading the way when it comes to the most advanced connectivity. SES is a trusted partner that powers inflight connectivity,” said Mike DeMarco, SES President of Mobility. More than 60 Airbus (A320NEO and A321XLR) and Embraer aircraft (E195-E2) will be equipped with SES services in the coming years. LATAM will be the largest airline in the region to offer service using SES’s new electronically steered a

Carta Rearchitects Private Capital Operations with Plugins for Claude29.7.2026 16:01:00 CEST | Press release

Firms managing billions in assets are cutting days of manual fund and portfolio work down to a single prompt — a shift now available to all Carta customers through Anthropic's official plugin directory. Carta, the connected platform and AI-native ecosystem for private capital, today announces broad availability of its suite of Plugins for Claude following the initial launch in April 2026. With more than 1,500 companies and firms already using the plugins, Carta is changing the way private capital teams — from founders to CFOs — fundamentally operate, bringing fund administration, cap table management, and dealflow analytics directly into the spreadsheets, presentations, and workflows they already use every day. "For the last decade, private capital operation teams have been held back by a hidden tax: the constant, manual handoff of data between disconnected systems," said Henry Ward, Carta CEO. "Carta is eliminating that broken loop entirely by embedding intelligence directly into the

Experian Recognized by Chartis Research for Advancing AI Model Governance in Quantitative Analytics50 202629.7.2026 15:00:00 CEST | Press release

Global data and technology company recognized for helping financial institutions accelerate AI innovation with trusted model governance, transparency and regulatory control Key Highlights Chartis Research recognized Experian as the category winner for Model Risk Management Environment in the Quantitative Analytics50 2026 report. Experian Ascend Platform™ enables organizations to move from model development to governed production with transparency, traceability and policy-driven controls. Recognition validates Experian's approach to helping lenders and financial institutions accelerate AI adoption while strengthening compliance, explainability and model risk governance. Experian today announced it has been recognized by Chartis Research as the winner in the Model Risk Management Environment category in the Quantitative Analytics50 2026 report. The recognition marks Experian's first appearance in the prestigious ranking and reinforces the company's position as a leading provider of data

Grid Dynamics Accelerates Enterprise AI-Native Transformation With Workforce Certification and GAIN Platforms Rollout29.7.2026 15:00:00 CEST | Press release

Key Takeaways: Grid Dynamics plans to have 90% of its engineers trained and certified on Anthropic and OpenAI platforms by the end of October 2026. At one of North America's largest home improvement retailers, Grid Dynamics has scaled its GAIN (Grid Dynamics AI Native) Platform for AI SDLC by expanding its agentic harness technology to more than 500 additional engineers. Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (“Grid Dynamics”), a leading provider of technology consulting, platform and product engineering, and AI-driven digital transformation services, today announced significant momentum in the adoption of its enterprise agentic AI solutions. Organizations across retail, financial services, manufacturing, CPG, and logistics industries are increasingly deploying Grid Dynamics’ agentic AI-native platforms and Forward Deployed Engineering (FDE)-led services to accelerate software delivery, improve operational efficiency, and transform business processes at scale. Grid Dynamics is wid

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye